United Therapeutics (STU:UTH) Beginning Cash Position : €1,111 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is United Therapeutics Beginning Cash Position?

United Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was €1,111 Mil.

United Therapeutics's quarterly Beginning Cash Position increased from Sep. 2023 (€1,000 Mil) to Dec. 2023 (€1,016 Mil) and increased from Dec. 2023 (€1,016 Mil) to Mar. 2024 (€1,111 Mil).

United Therapeutics's annual Beginning Cash Position increased from Dec. 2021 (€654 Mil) to Dec. 2022 (€845 Mil) and increased from Dec. 2022 (€845 Mil) to Dec. 2023 (€881 Mil).

United Therapeutics Beginning Cash Position Historical Data

The historical data trend for United Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Beginning Cash Position Chart

United Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

602.28

606.97

653.75

844.69

881.42

United Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															897.76	1,073.91	1,000.06	1,015.76	1,111.08

United Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

United Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics (STU:UTH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

UTHR:USA

Address

1040 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (STU:UTH) Headlines

No Headlines